Mice lacking the VPAC2 neuropeptide receptor developed much worse autoimmune brain disease because their regulatory T cells — the immune system's off-switch — were depleted and dysfunctional.
Tregs depleted and dysfunctional without VPAC2Regulatory T cells — the immune cells that prevent autoimmunity — were reduced in number, proliferation, and suppressive function in VPAC2-deficient mice, leading to severe autoimmune brain inflammation
What the researchers found
Mice lacking the VPAC2 receptor (which responds to the neuropeptides VIP and PACAP) developed much more severe autoimmune brain inflammation (EAE, the animal model for multiple sclerosis). Without VPAC2 signaling, the immune system shifted dramatically toward inflammation: pro-inflammatory Th1/Th17 responses were increased (TNF-α, IL-6, IFN-γ, IL-17), while protective Th2 and regulatory T cell (Treg) responses were reduced (IL-10, TGFβ, IL-4).
Most strikingly, Treg cells — the immune system's brakes — were both fewer in number and functionally impaired in VPAC2-deficient mice. This demonstrates that the VPAC2 receptor is essential for maintaining the pool of Tregs that prevent autoimmune attacks.
Why it matters
Multiple sclerosis is driven by the same kind of autoimmune attack on the brain that this model represents. This study identifies a specific neuropeptide receptor (VPAC2) as a critical controller of the immune balance that prevents autoimmunity. Drugs that activate VPAC2 could potentially expand the Treg population and dampen the overactive immune responses that drive MS and other autoimmune diseases.
The numbers in context
VPAC2 knockout vs wild type · enhanced clinical + histopathological EAE · increased TNF-α, IL-6, IFN-γ, IL-17 · decreased IL-10, TGFβ, IL-4 · reduced Treg abundance + proliferation + suppressive function
How the study worked
Researchers used genetically engineered VPAC2-knockout mice and wild-type controls. EAE (experimental autoimmune encephalomyelitis) was induced using MOG35-55 peptide. They measured clinical disease severity, histopathology, cytokine levels (qRT-PCR), T cell populations in the CNS, lymph nodes, and thymus, and tested Treg suppressive function in vitro.
Who was studied
VPAC2 receptor-deficient (VIPR2 knockout) mice and wild-type controls with induced EAE
What this study cannot tell us
Mouse EAE is a model for multiple sclerosis but doesn't perfectly replicate the human disease. Knockout studies show what happens when a receptor is completely absent from birth, which is different from blocking it pharmacologically in an adult. The study doesn't test whether activating VPAC2 could treat established disease. Specific sample sizes are not provided in the abstract.
How to read the evidence
This is a well-designed knockout mouse study with comprehensive immunological analysis. Published in Brain, Behavior, and Immunity. However, it's entirely preclinical, and knockout models represent extreme loss-of-function rather than the partial signaling changes that might occur naturally. Early-stage evidence.
When this study was published
Published in 2015. The role of VIP/PACAP in neuroimmunology continues to be studied. This finding about VPAC2 and Tregs remains a key reference in the field and supports ongoing interest in neuropeptide-based immunomodulation.
The bigger picture
This study clarifies a confusing puzzle in neuropeptide immunology. VIP-deficient and PACAP-deficient mice showed opposite EAE phenotypes, making it unclear which signals were protective. By knocking out VPAC2 specifically, this study shows that VPAC2 is the receptor responsible for the protective anti-inflammatory and Treg-expanding effects. This points to VPAC2 agonists as potential therapeutic targets for multiple sclerosis and other autoimmune conditions.
Questions still open
- Could a VPAC2 agonist drug expand the Treg population and treat established autoimmune disease?
- Does VPAC2 deficiency affect other autoimmune conditions beyond the brain, such as inflammatory bowel disease or rheumatoid arthritis?
- Is reduced VIP/PACAP-VPAC2 signaling a contributing factor in human multiple sclerosis?
Common questions
What are VIP and PACAP, and why do they matter for immunity?
Could targeting VPAC2 help treat multiple sclerosis?
Read the original research
VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses.
Brain, behavior, and immunity, 44, 167-175
Citation
Tan, Yossan-Var; Abad, Catalina; Wang, Yuqi; Lopez, Robert; Waschek, James. (2015). VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses.. Brain, behavior, and immunity, 44, 167-175. https://doi.org/10.1016/j.bbi.2014.09.020